Dyne Therapeutics (NASDAQ:DYN) Director Sells $3,122,168.80 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 147,760 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $21.13, for a total transaction of $3,122,168.80. Following the sale, the director directly owned 1,106,036 shares of the company’s stock, valued at approximately $23,370,540.68. The trade was a 11.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Up 1.4%

Shares of Dyne Therapeutics stock opened at $20.61 on Friday. The stock has a fifty day simple moving average of $18.43 and a 200 day simple moving average of $18.09. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The company has a market capitalization of $3.41 billion, a P/E ratio of -6.40 and a beta of 1.09. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the previous year, the company earned ($1.05) EPS. On average, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Monday, March 9th. HC Wainwright decreased their target price on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Monday, April 20th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 15th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.17.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors have recently added to or reduced their stakes in DYN. AQR Capital Management LLC purchased a new position in shares of Dyne Therapeutics in the first quarter worth about $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Dyne Therapeutics by 5.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock worth $597,000 after buying an additional 2,886 shares during the period. Goldman Sachs Group Inc. grew its stake in Dyne Therapeutics by 58.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after buying an additional 366,183 shares in the last quarter. Caxton Associates LLP purchased a new position in Dyne Therapeutics in the 1st quarter valued at approximately $157,000. Finally, Creative Planning raised its holdings in Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.